top of page

FDA approves Roche's Wilserdly with everolimus for ESR1-mutated advanced breast cancer

Writer: nuaxia
nuaxia
3 hours ago
2 min read

Roche's oral selective oestrogen receptor degrader Wilserdly has received FDA approval alongside everolimus for eligible patients with ESR1-mutated advanced breast cancer, supported by Phase III evidence of reduced disease progression risk.


The US Food and Drug Administration approved Wilserdly (giredestrant) in combination with everolimus on 16 November 2026 for adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer who meet the specified prior-treatment requirements, with mutation status established using an FDA-authorised test.


In the Phase III evERA study, the combination demonstrated a 62% reduction in the risk of disease progression or death compared with standard endocrine therapy plus everolimus in the ESR1-mutated population, while the FDA also authorised FoundationOne Liquid CDx as a companion diagnostic; the decision concerns advanced disease and is separate from the adjuvant application still under review.

Field

Content

Article Type

Approvals

Company

Roche

US Company

Genentech

Product Brand Name

Wilserdly

Active Ingredient

Giredestrant

Drug Classification

Oral selective oestrogen receptor degrader

Drug Class Abbreviation

SERD

Combination Medicine

Everolimus

Regulatory Authority

US Food and Drug Administration

Approval Date

16 November 2026

Regulatory Decision

FDA marketing approval

Geographic Scope

United States

Therapeutic Area

Oncology

Cancer Type

Breast cancer

Hormone Receptor Status

Oestrogen receptor-positive

HER2 Status

HER2-negative

Required Molecular Alteration

ESR1 mutation

Approved Disease Setting

Locally advanced or metastatic breast cancer

Patient Population

Eligible adults meeting the authorised prior-treatment and molecular-testing requirements

Treatment Regimen

Giredestrant plus everolimus

Supporting Clinical Trial

evERA

Clinical Trial Phase

Phase III

Key Efficacy Measure

Progression-free survival

Reported Relative Risk Reduction

62% reduction in risk of disease progression or death

Comparator

Standard endocrine therapy plus everolimus

Companion Diagnostic

FoundationOne Liquid CDx

Companion Diagnostic Status

FDA-authorised

Separate Regulatory Programme

Adjuvant breast cancer application

Adjuvant Application Status

Under review according to supplied summary

What Happened

The FDA authorised giredestrant with everolimus for a molecularly defined advanced breast cancer population.

Why It Matters

The approval introduces an additional targeted endocrine treatment option for patients with ESR1-mutated advanced breast cancer.

Clinical Significance

The pivotal study reported a substantial relative reduction in progression or death risk compared with the control regimen.

Regulatory Significance

The decision combines a new medicine approval with companion diagnostic authorisation.

Clinical Interpretation

The 62% figure is a relative risk reduction and should not be described as an absolute survival improvement.

Key Takeaway

Wilserdly plus everolimus is FDA-approved for eligible patients with ESR1-mutated advanced breast cancer.

What to Watch

US treatment uptake, molecular testing access, safety data, reimbursement and the separate adjuvant regulatory decision.

Primary Source

US Food and Drug Administration

Primary Source URL

https://www.fda.gov/drugs/cancer-approvals/fda-approves-giredestrant-combination-everolimus-er-positive-her2-negative-esr1-mutated-locally

Relevant Date

16 November 2026


Discover how nuaxia can support your next medical education initiative:

Comments

Rated 0 out of 5 stars.
No ratings yet

Add a rating
bottom of page